Skip to main content

Table 1 Clinicopathological features of HPV + ve/−ve OSCC patients and their relationship with miR-550a-3-5p expression

From: RETRACTED ARTICLE: Interplay between cancer cells and M2 macrophages is necessary for miR-550a-3-5p down-regulation-mediated HPV-positive OSCC progression

Characteristics HPV + ve OSCC (n = 25) HPV-ve OSCC (n = 45)
Cases Low miR-550a-3-5p (%) P Cases Low miR-550a-3-5p (%) P
Age (years)
 < 60 20 10 (50.00) 0.689 21 9 (42.86) 0.300
 ≥ 60 5 3 (60.00) 24 14 (58.33)
Gender
 Female 13 8 (61.54) 0.320 17 6 (35.29) 0.098
 Male 12 5 (41.67) 28 17 (60.71)
Drink
 Yes 7 4 (57.14) 0.748 31 15 (48.39) 0.587
 No 18 9 (50.00) 14 8 (57.14)
Smoke
 Yes 5 3 (60.00) 0.689 28 14 (50.00) 0.848
 No 20 10 (50.00) 17 9 (52.94)
Tumor Size
 T1-T2 9 2 (22.22) 0.025* 20 8 (40.00) 0.182
 T3-T4 16 11 (68.75) 25 15 (60.00)
Differentiation
 Well 4 2 (50.00) 0.265 14 6 (42.86) 0.438
 Moderate 13 5 (38.46) 19 9 (47.37)
 Poor 8 6 (75.00) 12 8 (66.67)
Clinical stage
 I-II 14 5 (35.71) 0.066 17 8 (47.06) 0.672
 III-IV 11 8 (72.73) 28 15 (53.57)
Nodal metastasis
 Yes 20 13 (65.00) 0.009* 26 13 (50.00) 0.862
 No 5 0 (0) 19 10 (52.63)
Recurrence
 Yes 1 1 (100.00) 0.327 8 5 (62.50) 0.477
 No 24 12 (50.00) 37 18 (48.65)
  1. * P < 0.05 was regarded as statistically significant in Chi square test